Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.77 |
| ▸ | TFEB | P19484 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 3/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coumarinic Acid Methyl Ether SCHEMBL29369917 | 1.00 | NFE2L2 (0.77) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL83064 | 1.00 | NFE2L2 (0.77) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL714857 | 1.00 | NFE2L2 (0.77) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL4743620 | 0.98 | NFE2L2 (0.74) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL10437229 | 0.98 | NFE2L2 (0.74) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL8351832 | 0.98 | NFE2L2 (0.74) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL28250887 | 0.95 | NFE2L2 (0.71) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL22092089 | 0.93 | KDM4E (0.68) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL2468602 | 0.93 | NFE2L2 (0.68) | NFE2L2TFEBKDM4EMAPTNPC1 | |
| Coumarinic Acid Methyl Ether SCHEMBL28320175 | 0.93 | NFE2L2 (0.68) | NFE2L2TFEBKDM4EMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 648 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497636-B2 | Recombinant Saccharomyces cerevisiae cells for cannabinoid production | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2025-12-16 | — | — | US | claimed |
| CN-119431432-A | Andrographolide diester derivative, preparation method and application | 西北农林科技大学 | 2025-02-14 | — | — | CN | claimed |
| CN-119215104-A | Traditional Chinese medicine extract and application thereof in preparation of cell necrotic apoptosis inhibitor | 河南中医药大学 | 2024-12-31 | — | — | CN | claimed |
| CN-118266572-A | Application of 3-methoxyphenyl-2-acrylic compound as bitter taste inhibitor | 华南理工大学 | 2024-07-02 | — | — | CN | claimed |
| CN-118027276-A | Multipolymer, preparation method and application thereof, negative electrode slurry, negative electrode plate and lithium ion battery | 北京卫蓝新能源科技有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-20230390195-A1 | STABLE COMPOSITIONS FOR INCRETIN MIMETIC COMPOUNDS | DELPOR, INC. | 2023-12-07 | — | — | US | claimed |
| CN-114163313-B | Method for selectively synthesizing EZ-stilbene by coupling ruthenium-catalyzed aryl diazonium salt with cinnamic acid | 中山大学 | 2023-11-03 | — | — | CN | claimed |
| CN-116687962-A | Composition for preventing or treating diabetes and application thereof | 青岛大学 | 2023-09-05 | — | — | CN | claimed |
| US-20220280494-A1 | COMPOSITIONS FOR SMALL MOLECULE THERAPEUTIC AGENT COMPOUNDS | DELPOR, INC. | 2022-09-08 | — | — | US | claimed |
| CN-114641291-A | Compositions of small molecule therapeutic compounds | 戴尔普尔有限公司 | 2022-06-17 | — | — | CN | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050161666-A1 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2005-07-28 | — | — | US | claimed |
| US-6916890-B1 | Thermally reworkable epoxy resins and compositions based thereon | HENKEL CORPORATION (US) | 2005-07-12 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1526584-A2 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | Samsung Electronics Co., Ltd (KR) | 2005-04-27 | — | — | EP | claimed |
| WO-2003031492-A1 | THERMALLY REWORKABLE EPOXY RESINS AND COMPOSITIONS BASED THEREO N | HENKEL CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | NFE2L2 1266/4885TFEB 957/4885KDM4E 1814/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | NFE2L2 3435/4885TFEB 1404/4885KDM4E 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.